02109nas a2200241 4500000000100000008004100001260001200042653001600054653000800070653001200078653002700090653001300117100001300130700001300143700001300156700001200169245012000181856008200301300000800383490000700391520145500398022001401853 2021 d c06/202110aCoinfection10aHIV10aleprosy10aPulmonary tuberculosis10aSyphilis1 aMasuka J1 aMkhize Z1 aPillay S1 aMosam A00aConcurrent pulmonary tuberculosis and lepromatous leprosy in a newly diagnosed HIV positive patient: a case report. uhttps://bmcpulmmed.biomedcentral.com/track/pdf/10.1186/s12890-021-01572-w.pdf a2070 v213 a

BACKGROUND: The leprosy-tuberculosis (TB) co-infection is rarely reported in recent times. However, this dual comorbidity is associated with high mortality and major morbidity. Unrecognised leprosy-TB co-infection may predispose affected patients to rifampicin monotherapy and subsequent drug resistance.

CASE PRESENTATION: A 35 year old migrant, human immunodeficiency virus (HIV) positive male worker presented with 6 month history of symmetric infiltrative nodular plaques of the face and distal, upper extremities. A few days after initial dermatology presentation, a sputum positive pulmonary tuberculosis diagnosis was made at his base hospital. Subsequent dermatology investigations revealed histology confirmed lepromatous leprosy and a weakly reactive rapid plasma reagin test. The presenting clinical features and laboratory results were suggestive of lepromatous leprosy coexisting with pulmonary tuberculosis in an HIV positive patient.

CONCLUSIONS: This case illustrates the occurrence of leprosy with pulmonary tuberculosis in an HIV infected patient and the difficulties in interpreting non-treponemal syphilis tests in these patients. This case also highlights the need for a high index of suspicion for co-infection and the need to exclude PTB prior to initiation of rifampicin containing multi-drug therapy (MDT). Interdisciplinary management and social support are crucial in these patients.

 a1471-2466